前言
一年一度的全球惡性良性腫瘤界盛會——美國臨床惡性良性腫瘤學會（ASCO）年會将于當地時間5月31日-6月4日召開。醫脈通特梳理了婦科惡性良性腫瘤領域的部分重磅研究進展。一起來看下吧！
Gynecologic Cancer
婦科惡性良性腫瘤
快速口頭報告
當地時間：
6月1日 – GMT-5 08:00
中原標準時間：
6月1日 – GMT+8 21:00
E451
01
摘要号：5512
信迪利單抗聯合紫杉醇和順鉑作為局部晚期宮頸癌新輔助治療的有效性和安全性：一項II期研究
标題：Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial.
報告人：劉繼紅教授
機關：中山大學惡性良性腫瘤防治中心
02
摘要号：5513
開放标簽、單臂、II期、多中心試驗（DURBAC）：度伐利尤單抗和BVAC-C治療一線鉑類化療失敗的HPV 16或18陽性宮頸癌
标題：An open label, single arm phase II, multicenter trial of durvalumab and BVAC-C, in patients with HPV 16- or 18-positive cervical cancer and failure of first-line platinum-based chemotherapy (DURBAC).
報告人：Chel Hun Choi, MD, PhD
機關：Department of Obstetrics and Gynecology, Samsung Medical Center
03
摘要号：5514
随機、III期CC3研究：尼妥珠單抗聯合同步放化療治療局部晚期宮頸鱗狀細胞癌
标題：Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized, phase 3 CC3 study.
報告人：王俊傑教授
機關：北京大學第三醫院
04
摘要号：LBA5515
III期、随機、雙盲、安慰劑/紫杉醇對照AXLerate-OC/GOG-3059/ENGOT OV-66研究：batiraxcept（AVB-S6-500）聯合紫杉醇治療鉑耐藥複發性卵巢癌
标題：AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer.
報告人：Katherine Cynthia Fuh, MD, PhD
機關：University of California, San Francisco
05
摘要号：LBA5516
suvemcitug聯合化療治療鉑類耐藥卵巢癌的随機、雙盲、安慰劑對照III期研究（SCORES）
标題：A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES).
報告人：袁光文教授
機關：中國醫學科學院惡性良性腫瘤醫院
06
摘要号：5517
口服環磷酰胺聯合貝伐珠單抗治療複發性卵巢癌、輸卵管癌和原發性腹膜癌
标題：Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer.
報告人：Mostafa Eyada
機關：University of Texas Medical Branch
07
摘要号：5518
一項随機試驗中惡性良性腫瘤幹細胞功能分析與複發性鉑耐藥卵巢癌患者客觀緩解率的關系
标題：Relationship of cancer stem cell functional assay and objective response rate of patients with recurrent platinum-resistant ovarian cancer in a randomized trial.
報告人：Thomas J. Herzog, MD
機關：University of Cincinnati
08
摘要号：5519
腹膜内化療的優化:随機II期GERCOR CHIMOVIP研究
标題：Optimization of intra-peritoneal chemotherapy: Randomized phase II GERCOR CHIMOVIP study.
報告人：Romain Cohen, MD, PhD
機關：Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP
09
摘要号：5520
多中心、開放标簽、随機、III期研究（SOC-1）的最終總生存期分析：二次減瘤術後序貫化療對比單純化療治療鉑敏感複發性卵巢癌
标題：Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial.
報告人：臧榮餘教授
機關：複旦大學附屬中山醫院
Gynecologic Cancer
婦科惡性良性腫瘤
口頭報告
當地時間：
6月2日 – GMT-5 08:00
中原標準時間：
6月2日 – GMT+8 21:00
Hall D2
01
摘要号：LBA5500
随機II期BrUOG 354的最終結果：納武利尤單抗單藥或聯合伊匹木單抗治療卵巢和其他腎外透明細胞癌
标題：Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.
報告人：Don S. Dizon, MD, FASCO, FACP
機關：Lifespan Cancer Institute, Rhode Island Hospital
02
摘要号：LBA5501
阿替利珠單抗與安慰劑聯合貝伐珠單抗和非鉑類化療治療複發性卵巢癌的比較：來自AGO-OVAR 2.29/ENGOT-ov34研究的最終總生存期和無進展生存期結果
标題：Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.
報告人：Frederik Marmé, MD, PhD
機關：Heidelberg University, University Hospital Mannheim
03
摘要号：5502
Vibostolimab聯合帕博利珠單抗治療經治的晚期錯配修複缺陷（dMMR）子宮内膜癌：II期KEYVIBE-005研究隊列B1的結果
标題：Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.
報告人：Carlos Rojas, MD
機關：Bradford Hill Clinical Research Center
04
摘要号：5503
靶向治療的III期婦科臨床試驗趨勢：過去12年的研究監督和藥物參與
标題：Trends in phase 3 gynecological clinical trials of targeted therapies: Study oversight and pharmaceutical involvement in the past 12 years.
報告人：Qiao Ruan, MD
機關：California Pacific Medical Center
05
摘要号：5504
根治性子宮切除術後高危早期宮頸癌患者同步放化療（CRT）後的輔助化療：NRG oncology/RTOG 0724/GOG-0724的結果
标題：Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG oncology/RTOG 0724/GOG-0724.
報告人：Anuja Jhingran, MD
機關：The University of Texas MD Anderson Cancer Center
06
摘要号：LBA5505
随機III期CARACO研究：新輔助化療後接受初次或間期惡性良性腫瘤細胞減滅術的晚期上皮性卵巢癌患者不進行淋巴結切除術
标題：Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial.
報告人：Jean-Marc Classe, MD, PhD
機關：Nantes Université
07
摘要号：5506
II期、随機、多中心NEO研究：奧拉帕利新輔助治療鉑敏感複發性進階别漿液性卵巢癌
标題：Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.
報告人：Stephanie Lheureux, MD, PhD
機關：Princess Margaret, University Health Network
08
摘要号：5507
21世紀美國子宮内膜癌和肥胖的趨勢
标題：Endometrial cancer and obesity trends in the United States in the 21st century.
報告人：Alex Andrea Francoeur, MD
機關：UC Irvine Health
09
摘要号：5508
絕經前臨床I期子宮内膜癌患者激素治療的長期生存預後
标題：Long-term survival outcomes for hormonal therapy in premenopausal patients with clinical stage I endometrial cancer.
報告人：Yukio Suzuki, MD, PhD
機關：Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons
備注：排名不分先後，按照摘要号進行
如有遺漏或任何問題，請給我們留言~
參考來源：https://meetings.asco.org/meetings/2024-asco-annual-meeting/316/program-guide/scheduled-sessions
編輯：Uni
排版：Uni
執行：Uni
醫脈通是專業的線上醫生平台，“感覺世界醫學脈搏，助力中國臨床決策”是平台的使命。醫脈通旗下擁有「臨床指南」「用藥參考」「醫學文獻王」「醫知源」「e研通」「e脈播」等系列産品，全面滿足醫學工作者臨床決策、擷取新知及提升科研效率等方面的需求。
本平台旨在為醫療衛生專業人士傳遞更多醫學資訊。本平台釋出的内容，不能以任何方式取代專業的醫療指導，也不應被視為診療建議。如該等資訊被用于了解醫學資訊以外的目的，本平台不承擔相關責任。本平台對釋出的内容，并不代表同意其描述和觀點。若涉及版權問題，煩請權利人與我們聯系，我們将盡快處理。